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1. INTRODUCTION {#mgg3750-sec-0005}
===============

As the most incident tumor among women worldwide, breast cancer also causes the highest number of deaths in the female population, especially in developing countries where the diagnosis of late‐stage disease is made in most cases (World Health Organization, [2018](#mgg3750-bib-0037){ref-type="ref"}). Breast cancer is also a heterogeneous disease, where the individual\'s genetics in combination with the influence of tumor histological type, molecular subtype, and tumor microenvironment contribute to disease progression. A better understanding of these factors in relation to early diagnosis and disease treatment impacting overall survival is critical (Cecilio et al., [2015](#mgg3750-bib-0007){ref-type="ref"}). In addition, differences between populations and also environmental and cultural factors significantly affect the origin and evolution of the disease, and therefore bring additional therapeutic challenges (IARC, [2014](#mgg3750-bib-0014){ref-type="ref"}).

Ductal carcinomas account for more than 70% of breast tumors and include all histological types that cannot be classified into defined types. Their prognosis depends mainly on the molecular subtype and other features such as stage that includes tumor size, affected lymph nodes, and the presence of metastasis (IARC, [2014](#mgg3750-bib-0014){ref-type="ref"}). Among the histological types of breast tumors, mucinous carcinomas of the breast are rare and comprise 1%--6% of all breast tumor cases, especially in women over 75 years of age (Ha, Deleon, & Deleon, [2013](#mgg3750-bib-0012){ref-type="ref"}). Genomic studies involving this type of tumor are understudied, in part because of its low incidence. A portion of the cases that did not respond well to standard‐of‐care treatments were characterized as presenting positivity for *ERBB2* and *P53*, with a higher probability of metastasis. Cases that present the mucinous histological type in less than 90% of the tumor or, in association with invasive ductal tumors, also tend to be more aggressive (Lacroix‐Triki et al., [2010](#mgg3750-bib-0016){ref-type="ref"}). In addition, chromosome analysis in pure mucinous tumors in conjunction with other histological types showed gains in 1q and 16p arms and losses in the 16q and 22q arms, despite lower genetic instability compared to invasive ductal tumors. Studies have shown that a number of genes such as *ERBB2*, *FGFR1*, *CCND1*, *FGF3*, *FGF4*, *FGF19*, *PIK3CA*, *BRCA1*, *TSC2*, *STK11*, *AKT3,* and *ESR1*, among others, present changes in tumors of this type (Lei, Yu, Chen, Chen, & Wang, [2016](#mgg3750-bib-0018){ref-type="ref"}; Ross et al., [2016](#mgg3750-bib-0031){ref-type="ref"}). Hence, a better understanding is needed of altered genomic landscape in aggressive, treatment‐refractory mucinous breast tumors.

Majority of defined breast cancer molecular subtypes were derived from ductal invasive breast tumors, and largely lacked profiling from other histological types of breast tumors (Dieci, Orvieto, Dominici, Conte, & Guarneri, [2014](#mgg3750-bib-0008){ref-type="ref"}; Perou et al., [2000](#mgg3750-bib-0028){ref-type="ref"}; The Cancer Genome Atlas \[TCGA\], [2012](#mgg3750-bib-0035){ref-type="ref"}). Few studies have described how molecular features from different histological types may influence treatment response (Caldarella et al., [2013](#mgg3750-bib-0006){ref-type="ref"}; Weigelt et al., [2008](#mgg3750-bib-0036){ref-type="ref"}). Mucinous tumors are often described as Luminal A, and recent studies have shown that this subtype tended to have worse responses to cytotoxic agents and develop resistance to chemotherapy compared earlier to other histological subtypes (Araki & Miyoshi, [2018](#mgg3750-bib-0003){ref-type="ref"}; Martelotto, Ng, Piscuoglio, Weigelt, & Reis‐Filho, [2014](#mgg3750-bib-0019){ref-type="ref"}).

Although breast cancer comes in many histological forms, the mucinous histological type remains understudied, in part due to its low incidence. In addition, the Brazilian population of breast cancer patients is understudied regardless of the tumor phenotype. Current demographic data shows that the Brazilian population is composed of mixed ethnicities (Instituto Brasileiro de Geografia e Estatística \[IBGE\], [2018](#mgg3750-bib-0015){ref-type="ref"}). Since Brazil is a genetically underrepresented population, studies that include Brazilian cohorts may uncover previously unknown genetic drivers of therapeutic resistance and lead to the discovery of new biomarkers. The genetic composition of tumors in the Brazilian population is also dissimilar from that of populations living in other regions of the globe, even in neighboring Latin America countries, since the patterns of colonization and intrinsic miscegenation between colonizers and the native populations vary markedly across these countries (Giolo et al., [2012](#mgg3750-bib-0010){ref-type="ref"}; Popejoy & Fullerton, [2016](#mgg3750-bib-0029){ref-type="ref"}).

In this study, we compare the genomic features in terms of copy number variations (CNVs) in mucinous and nonmucinous luminal breast tumors of a Brazilian cohort. With this methodological approach, we were able to describe major CNV imbalances in mucinous tumors versus ordinary luminal A/B tumors in association with clinical and pathological features.

2. SUBJECTS AND METHODS {#mgg3750-sec-0006}
=======================

The procedures for obtaining the samples used in this study, as well as the informed consent form signed by all the women participating in this study, followed the recommendations of the Declaration of Helsinki and were approved by the Research Committee of CAISM---Women\'s Hospital/UNICAMP (approved project n.° 082/2013) on 12/12/2013 and by the Research Ethics Committee of UNICAMP and CONEP---National Research Committee (approved project n.° 1.166.843) on 7/30/2015. Tumor and blood samples of women who agreed to participate in the study and signed the consent form for this purpose were collected by the Division of Gynecological Oncology and Breast Pathology of CAISM---Women\'s Hospital/UNICAMP. Medical records were reviewed to obtain women clinical and epidemiological data. For this study, only ductal and mucinous tumors with or without other minor components were selected after the histopathological characterization of the biopsy. A skilled pathologist selected tumor and normal areas for microdissection. Tumor areas were used to obtain 10μm fragments from which DNA extraction using phenol/chloroform protocol was performed. A similar protocol was used for DNA retrieval from blood samples.

DNA was verified in agarose gel and considered adequate only when hosting \>80% of integrity. DNA was then diluted at concentrations between 40 and 60 ng/μl, which were verified by the Epoch spectrophotometer (Biotek^®^, Winooski, VT). These concentrations are suitable for use with Affymetrix^®^ Cytoscan^™^ HD Array assay kits (Thermo Fisher Scientific Inc., Santa Clara, CA). The protocol was performed as per manufacturer recommendations, comprising the steps of preparing the genomic DNA, digestion, ligation, PCR, purification, quantification, fragmentation, labeling, hybridization, washing, staining, and chip scanning. After scanning, data was processed by Affymetrix Molecular Diagnostic Software (AMDS) and quality control was generated by ChAS analysis software (Chromosome Analysis Suite, Affymetrix^®^). 48 chips were hybridized for the tumor samples and 48 chips for the blood samples of the same woman, the latter being used as control of constitutive CNVs.

For CNV analysis, data were normalized via the ASCRMA and raw copy algorithms. Then, the normalized data was segmented using the Parent‐specific circular binding segmentation (Olshen et al., [2011](#mgg3750-bib-0025){ref-type="ref"}), copynumber, GADA, and CBS protocols. Only alterations contemplating at least 25 microarray probes for deletions or 50 probes for amplifications were considered, along with fragments of 100kb and with low‐rank representation (LRR) ≤ −0.3 for deletions and LRR ≥0.3 for amplifications. The data were also evaluated by the intersection of methods performed and described above: only samples with CNVs present in three or more of the methods were considered as altered for the variation found. Afterward, two statistical tests were applied to rank the most relevant CNVs by comparing between ductal and mucinous samples and also to evaluate the most relevant CNVs in relation to the clinical and pathological characteristics. Functional pathways associated with these CNVs were searched using DAVID 6.8 (The Database for Annotation, Visualization and Integrated Discovery, p‐value ≤0.05) (Huang, Sherman, & Lempicki, [2009](#mgg3750-bib-0013){ref-type="ref"}) and UCSC Table Browser was used to retrieve information on variants already described that are in association with the verified CNVs.

3. RESULTS {#mgg3750-sec-0007}
==========

Table [1](#mgg3750-tbl-0001){ref-type="table"} shows the clinical and epidemiological features of the women included in the study, per tumor histological type. The majority of the women were above 45 years of age and were postmenopausal. Disease stage was predominantly I or II. About 81% of the women were Caucasian versus 19% Afro‐descendants. Fourteen women reported one or more cases of breast cancer in their families. Majority of the cases (*n* = 35) were classified as Luminal A, 11 Luminal B and 2 Luminal B/HER2 enriched.

###### 

Description of the clinical and epidemiological features of the women included in the study

                                     Mucinous Samples   Ductal Samples        
  ---------------------------------- ------------------ ---------------- ---- ----
  Age at diagnosis                                                             
  35--45                             0                  0                3    6
  \>45                               10                 21               35   73
  Ethnicity                                                                    
  Caucasian                          9                  19               30   62
  Afro‐descendant                    1                  2                8    17
  Menopausal status                                                            
  Post                               9                  19               28   58
  Pre                                1                  2                10   21
  Disease stage                                                                
  I/II                               9                  19               27   57
  III                                1                  2                11   22
  Familial history---breast cancer                                             
  Yes                                1                  2                13   27
  No                                 9                  19               25   52
  Molecular subtype                                                            
  Luminal A                          7                  15               28   58
  Luminal B                          1                  2                10   21
  Luminal B/*HER2*                   2                  4                0    0
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The frequencies of CNVs, by chromosome, in relation to clinical/pathological data are shown in Table [2](#mgg3750-tbl-0002){ref-type="table"}. Interestingly, the described CNVs related to later disease stage and presence of family history were found on the same chromosomes (chr 5, 19 and 21), although more CNVs in chromosome 19 (46%) were associated with late stage and more CNVs in chromosome 21 (49%) were associated with family history. For histological type, when comparing ductal to mucinous breast carcinomas, CNVs in chromosomes 1 and 8 accounted for almost 49% of all alterations found in the mucinous tumors analyzed. Similarly, CNVs in chromosome 19 summed to 46.27% of alterations related to later disease stage, alterations in chromosome 21 summed to 49.42% for familial history presence and chromosomes 1 and 17 summed to 31.08% for ethnicity (Caucasian).

###### 

Percentage of CNVs found, by chromosome, including association with clinical and pathological features

                      Chromosome   Percentage (%)
  ------------------- ------------ ----------------
  Histological type   chr8         27.81
  chr1                21.16        
  chr15               0.88         
  chr16               7.00         
  chr14               6.67         
  chr12               4.82         
  chr11               4.80         
  chr18               4.32         
  chr17               4.09         
  chr19               3.16         
  chr6                2.50         
  chr13               2.50         
  chr20               1.77         
  chr22               1.54         
  chr3                1.47         
  chr9                1.37         
  chr21               1.23         
  chr7                0.95         
  chr4                0.90         
  chr2                0.62         
  chr10               0.35         
  chr5                0.10         
  Ethnicity           chr1         17.85
  chr17               13.23        
  chr10               12.15        
  chr19               12.12        
  chr8                8.71         
  chr16               7.88         
  chr11               5.83         
  chr14               5.51         
  chr20               2.61         
  chr13               2.59         
  chr6                2.11         
  chr12               1.82         
  chr21               1.54         
  chr3                1.51         
  chr5                1.14         
  chr22               0.87         
  chr2                0.71         
  chr4                0.70         
  chr7                0.52         
  chr9                0.29         
  chr18               0.21         
                                   
  Disease stage       chr19        46.27
  chr21               35.07        
  chr5                18.66        
                                   
  Familial history    chr21        49.42
  chr19               28.79        
  chr5                21.79        
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Table [3](#mgg3750-tbl-0003){ref-type="table"} describes the genes related to CNVs in each chromosome, according to the features they were most associated with. Logistic Regressions and Random Forests models were used to assess these regions, comparing the genomic profiles of the samples, in which a power of discrimination (AUC) of 73% was obtained. The CNVs ranking data distinguishing between histological types and other clinical/pathological tumors' characteristics were assessed to evaluate how these alterations contributed to the separation between considered groups.

###### 

Description of chromosomes containing most alterations per feature and related genes, verified by logistic regression/random forests

               Histological type   Familial history   Disease stage   Ethnicity                                                                                              
  ------------ ------------------- ------------------ --------------- -------------- ------------- --------------- ------------- -------------- ------------- -------------- -------------
  Chromosome   1                                      8               21             19                                                                       1              17
  Percentage   21.16%                                 27.81%          49.42%         46.27%                                                                   17.85%         13.23%
  Genes        *FNDC5*             *NBPF13P*          *TATDN1*        *SAMSN1*       *FKRP*        *C19orf70*      *C19orf24*    *SYNGR4*       *CENPBD1P1*   *RORC*         *MEIS3P2*
               *PHBP12*            *CC2D1B*           *RNF139‐AS1*    *SLC19A1*      *ZNF257*      *CRX*           *SF3A2*       *BSPH1*        *CTBP2P7*     *EMBP1*        *DDX42*
               *STXBP3*            *ZC3H11A*          *LYN*           *RAD23BLP*     *ZNF573*      *ZNF439*        *UHRF1*       *GCDH*         *ZNF155*      *SLC2A1‐AS1*   *CRLF3*
               *DIRAS3*            *PGBD2*            *DLGAP2*        *PRDM15*       *ZNF468*      *ZNF700*        *PLEKHA4*     *ZNF814*       *SEMA6B*      *C1orf131*     *NXN*
               *MYCL*              *POLR3C*           *DMTN*          *PCBP3*        *ZSCAN5A*     *KLK8*          *SNORD23*     *TMEM143*      *DOT1L*       *RFWD2*        *APOH*
               *FKSG48*            *TRIM58*           *ZNF250*        *ERG*          *MIR3940*     *KLK15*         *OR7A10*      *CYP4F2*       *LMTK3*       *HHAT*         *ATAD5*
               *LMO4*              *HHIPL2*           *ANK1*          *LINC00320*    *ZNF725P*     *RNU6‐902P*     *DBP*         *PCGF7P*       *RPL23AP2*    *RGL1*         *CCDC144CP*
               *PPIE*              *CFL1P2*           *RNF139*        *RPL31P1*      *SLC27A5*     *SAFB*          *KCNN1*       *RN7SL513P*    *TTYH1*       *RNU2‐12P*     *PSMD7P1*
               *VAV3*              *BMP8B*            *LINC01109*     *RPL34P3*      *ZFP30*       *ZNF606*        *SPPL2B*      *SSC5D*        *ZNF793*      *GPATCH2*      *CTNS*
               *ZZZ3*              *EIF4G3*           *COL22A1*       *ITGB2*        *ZNF222*      *ZIM2*          *ZNF780B*     *EHD2*         *SIGLEC7*     *FMO4*         *MYO18A*
               *LRRC7*             *SYDE2*            *PXDNL*         *DIP2A*        *ZNF121*      *SNRPEP4*       *NTF4*        *LENG8*        *ZNF432*      *ZBTB41*       *TRIM16L*
               *AK5*               *AK2*              *TTPA*          *LINC00159*    *CHMP2A*      *OSCAR*         *MIR3189*     *BIRC8*        *LAIR1*       *CYCSP4*       *CCDC47*
               *BRINP2*            *PBX1*             *FAM66A*        *RPL23AP4*     *ZNF69*       *DHDH*          *CYTH2*       *GYS1*         *SIGLEC6*     *LAMB3*        *RAI1‐AS1*
               *PIGK*              *SF3B4*            *IKBKB*         *SNX19P1*      *UQCR11*      *MAN2B1*        *RNA5SP468*   *ZNF285*       *ZNF135*      *PLD5*         *SREBF1*
               *C1orf185*          *MACF1*            *CSMD1*         *C21orf91*     *ZNF737*      *TPM3P6*        *RFX2*        *CALR*         *SAFB2*       *ARID4B*       *MAP2K3*
               *GCLM*              *S100PBP*          *LRRC69*        *OR4K11P*      *CTU1*        *ZNF813*        *SPHK2*       *SIPA1L3*      *MEGF8*       *RGS7*         *SCPEP1*
               *COL24A1*           *TFAP2E*           *NPM1P6*        *BACH1*        *SIGLEC5*     *ZNF446*        *RASIP1*      *ZNF571‐AS1*   *ZNF433*      *C1orf100*     *ATP2A3*
               *S100A16*           *SMYD3*            *PKHD1L1*       *TTC3*         *SLC5A5*      *ZNF675*        *CLPP*        *ZNF780A*      *RPL23AP80*   *ESRRG*        *SNORD3C*
               *ABL2*              *DISP1*            *CLVS1*         *PRMT2*        *CACNG8*      *RNU6‐1337P*    *ZNF324*      *ZNF254*       *RFXANK*      *OPTC*         *SMCR5*
               *RNF115*            *ZMPSTE24*         *LYPLA1*        *SLC37A1*      *GALP*        *MIR517C*       *ZNF473*      *ZNF726*       *PTPRS*       *WDR64*        *ZSWIM5P2*
               *MRPS6P2*           *MIR4423*          *PRKDC*         *TTC3‐AS1*     *ZNF221*      *WDR87*         *ZNF878*      *SYDE1*        *CD70*        *DENND1B*      *RAI1*
               *THBS3*             *CFHR2*            *MFHAS1*        *PKNOX1*       *POU2F2*      *MIR520H*       *KLKP1*       *KIR3DP1*      *RNU6‐751P*   *CD1A*         *MIR33B*
               *GNG12‐AS1*         *RPS15AP6*         *FAM66B*        *CHODL‐AS1*    *C5AR2*       *MIR521‐1*      *KCNJ14*      *MYO9B*        *NPAS1*       *PPP1R12B*     *CDRT15L2*
               *OXCT2*             *SMAP2*            *RAB2A*         *HSF2BP*       *MEF2B*       *FUT2*          *RNA5SP465*   *KHSRP*        *GRIK5*       *ZP4*          *BRIP1*
               *TUBB8P6*           *USP33*            *ASPH*          *LSS*          *ELSPBP1*     *MIR522*        *RNA5SP464*   *CCDC130*      *FPR1*        *GNPAT*         
               *HENMT1*            *TRIT1*            *MYOM2*         *SNORD74*      *KDELR1*      *ZNF571*        *LSM4*        *CYP4F3*                     *FCGR1A*        
               *STRIP1*            *CCNT2P1*          *CYCSP22*       *TIAM1*        *POLR2E*      *FUT1*          *MED25*       *CACNA1A*                    *HNRNPA1P59*    
               *YARS*              *ASTN1*            *TRMT12*        *RNU4‐45P*     *ZNF628*      *ZNF582*        *MAU2*        *TMEM145*                    *FLVCR1*        
               *PLD5*              *RLF*              *ELP3*          *GRIK1‐AS2*    *MZF1*        *MIR518A2*      *ZNF235*      *CA11*                       *IBA57*         
               *ROR1*              *MTX1*             *SGCZ*          *YBEY*         *ZNF43*       *FTL*           *ZNF611*      *GDF15*                      *COLGALT2*      
               *CHRM3*             *MUC1*             *SNORD112*      *GTF2IP2*      *C19orf18*    *CSNK1G2‐AS1*   *LINC00662*   *PRR19*                      *SLC35F3*       
               *SPATA17*           *GIPC2*            *EBAG9*         *LINC00314*    *ZNF45*       *FAM90A28P*     *TUBB4A*      *SYT3*                       *PBX1*          
               *DAB1*              *TMEM56*           *THAP1*         *C21orf58*     *TNFSF9*      *OR1AB1P*       *MIR4321*     *SULT2A1*                    *MDM4*          
               *RGS7*              *FUBP1*            *FUT10*         *SCAF4*        *SNRNP70*     *ZNF420*        *TMEM161A*    *ZNF283*                     *TTC13*         
               *RN7SL854P*         *MIR1256*          *TRPS1*         *LINC00315*    *MIR1227*     *MIR519A2*      *KLK5*        *SULT2B1*                    *LHX4*          
               *EEF1A1P14*         *CFHR1*            *FER1L6‐AS2*    *TIMM9P2*      *IGSF23*      *MIR516A2*      *TMEM160*     *LYPD5*                      *CDC73*         
               *RNU6‐877P*         *RNF19B*           *FGFR1*         *KCNE2*        *TNFAIP8L1*   *MIR7‐3*        *BAX*         *GTF2F1*                     *CDC42BPA*      
               *AKT3*              *HPCAL4*           *FBXO32*        *RPS26P5*      *SIGLEC9*     *MIR516A1*      *MIR4323*     *ALKBH7*                     *COL11A1*       
               *ST6GALNAC5*        *MIR4421*          *SNTG1*         *DSTNP1*       *KIR3DL3*     *MIR527*        *LGALS14*     *PRR12*                      *CFHR2*         
               *RN7SL370P*         *LPGAT1*           *LPL*           *H2AFZP1*      *ZNF578*      *MIR519A1*      *KCNA7*       *TPRX1*                      *HMGN1P5*       
               *RNF11*             *FMN2*             *NRG1*          *DYRK1A*       *ZNF350*      *BTBD2*         *OR7C2*       *EPN1*                       *HIST2H3D*      
               *GJA5*              *FNDC7*            *LINC01111*     *HMGN1P2*      *CABP5*       *THEG*          *OR7A5*       *ZNF490*                     *SLC2A1*        
               *CLCA4*             *DNAJB4*           *POLB*          *MIRLET7C*     *JSRP1*       *SAE1*          *JUND*        *RNU6‐982P*                  *TRMT1L*        
               *ARL5AP3*           *KIF14*            *SLC10A5*       *CYP4F29P*     *URI1*        *ZNF566*        *BCL3*        *MAMSTR*                     *GNG4*          
               *DTL*               *TRAF5*            *FER1L6*        *FAM207A*      *SPACA4*      *RPS9*          *FAM83E*      *IZUMO1*                     *PTPN14*        
               *NSRP1P1*           *RCOR3*            *GSR*           *LIPI*         *ZNF28*       *ASF1B*         *KIAA1683*    *RPL39P38*                   *CFHR1*         
               *ACOT11*            *LIN9*             *ENPP2*         *UBASH3A*      *ZNF709*      *SUGP2*         *RN7SL693P*   *PRRG2*                      *KLHL12*        
               *PLA2G12AP1*        *DDX59*            *C8orf22*       *APP*          *LRRC25*      *ZNF702P*       *CYP4F8*      *RN7SL121P*                  *CSRP1*         
               *TAF1A*             *KIAA1522*         *ZNF705G*       *LINC00205*    *PSPN*        *TRIM28*        *SLC25A42*    *KLK9*                       *MROH9*         
               *HMCN1*             *TRIM46*           *IMPA1*         *ANKRD30BP1*   *ERCC1*       *SEC1P*         *RPL7P51*     *NAT14*                      *CD46*          
               *NME7*              *RNA5SP52*         *MIR4662A*      *MIR3156‐3*    *AP3D1*       *CEP89*         *NOSIP*       *SIGLECL1*                   *HIST2H2BF*     
               *SLC35F3*           *TMEM54*           *DPY19L4*       *PDE9A*        *ZNF470*      *ZNF546*        *RN7SL708P*   *ZNF841*                     *KDM5B*         
               *MIR92B*            *FAM129A*          *RNF170*        *SAMSN1‐AS1*   *ZNF761*      *PPP1R14A*      *SIGLEC18P*   *ACSBG2*                     *BRINP3*        
               *CDC42BPA*          *C8B*              *WISP1*         *MCM3AP‐AS1*   *CRB3*        *DENND1C*       *PGPEP1*      *SPINT2*                     *CRB1*          
               *CDKN2C*            *ZNF672*           *DECR1*         *NCAM2*        *PPP1R13L*    *ZBTB45*        *ZNF676*      *KLK6*                       *PDE4B*         
               *EVI5*              *GBAP1*            *RPS3AP30*      *NRIP1*        *ZNF808*      *NDUFA3P1*      *GLTSCR1*     *KLK10*                                      
               *FAM102B*           *RNA5SP44*         *FABP5*         *TRAPPC10*     *ZNF233*      *ZNF835*        *GLTSCR2*     *KLK7*                                       
               *SRGAP2*            *TPR*              *RPL5P23*       *COL18A1*      *RUVBL2*      *RPL28*         *ZSCAN5C*     *ZNF763*                                     
               *MRPS21*            *NOTCH2*           *PCM1*          *POTED*        *CEACAM22P*   *ATP1A3*        *LONP1*       *LRG1*                                       
               *OSBPL9*            *TTC39A*           *XKR6*          *CRYAA*        *CEACAM16*    *PLIN3*         *SLC25A41*    *VN1R85P*                                    
               *WDR63*             *USP25*            *RNU6‐756P*     *MRPL51P2*     *KLK12*       *ZNF443*        *MIR7‐3HG*    *VN1R84P*                                    
               *HSPE1P25*          *CSMD2*            *DEFB109P1B*    *MCM3AP*       *KLK14*       *DYRK1B*        *TCF3*        *LRRC4B*                                     
               *HPCA*                                 *SYBU*          *BRWD1‐IT1*    *NR2C2AP*     *NTN5*          *ISOC2*       *HOOK2*                                      
               *LINC01057*                            *CHD7*          *WDR4*         *UBE2S*       *ZNF415*        *TPRX2P*      *ZFP82*                                      
               *NFASC*                                *MCM4*          *MIR125B2*     *LGALS17A*    *CGB5*          *ZNF100*      *CGB7*                                       
               *RAVER2*                                               *RNU1‐98P*     *FBL*         *ARHGEF1*       *LGALS16*     *DPP9*                                       
               *DDAH1*                                                *PTTG1IP*      *RDH13*       *ZNF563*        *PAFAH1B3*    *KLK13*                                      
               *OR2W3*                                                *SIK1*         *CIRBP*       *SLC25A23*      *ZNF665*      *ZFP28*                                      
               *GLMN*                                                 *ERLEC1P1*     *HDGFRP2*     *SMIM7*         *RPL18*       *CCDC9*                                      
               *RN7SKP98*                                             *CBS*          *MIDN*        *RNU6‐1028P*    *TTC9B*       *ZNF225*                                     
               *NEXN‐AS1*                                             *DSCAM*        *TM6SF2*      *KLK11*         *RPL18A*      *ZNF226*                                     
               *NEXN*                                                 *TMPRSS15*     *PRKACA*      *RNU6‐1041P*    *SEPT7P8*     *ZNF320*                                     
               *DPYD*                                                 *RNU6‐1326P*   *HAPLN4*      *PLIN4*         *ZNF816*      *ZNF227*                                     
               *JAK1*                                                 *LINC00308*    *CYP4F22*     *MLLT1*         *ZNF540*      *ZNF112*                                     
               *PSMB2*                                                *PPIAP1*       *FEM1A*       *NCAN*          *ZNF92P2*     *RABAC1*                                     
               *PIAS3*                                                *PCNT*         *CLC*         *MAP3K10*       *SNORD112*    *ZNF805*                                     
               *TMCO2*                                                *MIR99A*       *ZNF568*      *TPM3P9*        *ZNF92P3*     *ZNF230*                                     
               *RN7SKP12*                                             *RSPH1*        *MAST3*       *MIER2*         *HKR1*        *KLK4*                                       
               *PDE4B*                                                *PCP4*         *RNU6‐165P*   *NLRP8*         *LENG8‐AS1*   *HMGN1P32*                                   
               *RNA5SP21*                                             *PSMG1*        *KDM4B*       *GRWD1*         *TICAM1*      *RPL36*                                      
               *TMEM56‐RWDD3*                                         *MIR1283‐2*    *TPM4*        *ZNF83*         *TINCR*       *ZNF564*                                     
               *RNA5SP20*                                             *LINC00322*    *LSM7*        *ABCA7*         *BRD4*        *CD33*                                       
               *WLS*                                                  *MIR5692B*     *ZNF234*      *CSNK1G2*       *ARRDC5*      *ZNF223*                                     
               *SV2A*                                                 *LINC00307*    *HSD11B1L*    *ONECUT3*       *SNORA68*     *ZNF224*                                     
               *CACHD1*                                               *RUNX1*        *ZNF321P*     *RPL32P34*      *ZNF574*      *MIR3188*                                    
               *RNU7‐121P*                                            *ADARB1*       *RPSAP58*     *KIR2DP1*       *INSR*        *PLEKHJ1*                                    
               *GPATCH2*                                              *GRIK1*        *FCGBP*       *ZSCAN5B*       *CIRBP‐AS1*   *CGB8*                                       
               *FAF1*                                                 *ERVH48‐1*     *ARMC6*       *KIR3DL1*       *RNA5‐8SP4*   *ZNF208*                                     
               *ORC1*                                                 *C2CD2*        *CATSPERD*    *CGB1*          *CEACAM19*    *ATP8B3*                                     
               *PRPF38B*                                              *POFUT2*       *CYP4F23P*    *MIR5684*       *ADAT3*       *FAM90A27P*                                  
               *ENAH*                                                 *TPT1P1*       *CLEC11A*     *SUGP1*         *SCAMP4*      *BBC3*                                       
               *ST7L*                                                 *RNU6‐286P*    *SYCE2*       *KLK2*          *GATAD2A*     *SIGLEC14*                                   
               *NUDT17*                                               *CLDN14*       *ZNF799*      *CCDC124*       *LEUTX*       *ARRDC2*                                     
               *EPS15*                                                *VDAC2P1*      *GRIN2D*      *C19orf81*      *ZNRF4*       *SHISA7*                                     
               *ZFYVE9*                                               *NDUFV3*       *ACER1*       *PLIN5*         *ZNF284*      *ZC3H4*                                      
               *NFIA*                                                 *BRWD1*        *AMH*         *ATP5D*         *ZNF404*      *RCN3*                                       
               *PDE4DIP*                                              *U2AF1*        *PGK1P2*      *KIR2DL1*       *C5AR1*       *DEDD2*                                      
               *IRF6*                                                 *RNU6‐113P*    *UBE2M*       *KIR2DL3*       *SHANK1*      *RAD23A*                                     
                                                                      *KRTAP10‐3*                  *KIR2DL4*       *ZNF585A*     *AKT2*                                       
                                                                                                                   *IL12RB1*     *HIPK4*                                      
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Table [4](#mgg3750-tbl-0004){ref-type="table"} summarizes the annotation findings in terms of functional pathways closely associated to the CNV‐related genes found in the most altered chromosomes, depending on the analyzed trait. Pathways involved with alternative splicing and polymorphisms were mainly associated with most of the altered regions.

###### 

Functional annotation of genes and enriched pathways associated with CNVs described (DAVID 6.8 Database)

  Feature             Chr.                   Pathway/function       Gene count   \%       *p*‐value
  ------------------- ---------------------- ---------------------- ------------ -------- -----------
  Histological type   1                      Alternative splicing   37           57.8     0.0017
                      Splice variant         29                     45.3         0.0096   
                      Cytoplasm              20                     31.2         0.015    
                      Mutagenesis site       11                     17.2         0.041    
  8                   Polymorphism           87                     55.1         0.021    
                      Alternative splicing   81                     51.3         0.0056   
                      Phosphoprotein         69                     43.7         0.0014   
                      Splice variant         67                     42.4         0.0012   
                      Cytoplasm              44                     27.8         0.0047   
  Familial history    21                     Alternative splicing   40           40.8     0.0043
                      Phosphoprotein         35                     35.7         0.0014   
                      Protein binding        32                     32.7         0.038    
                      Nucleus                28                     28.6         0.0003   
                      Cytosol                18                     18.4         0.0055   
  Disease stage       19                     Polymorphism           224          53.8     0.013
                      Nucleus                149                    35.8         1E‐12    
                      Transcription          118                    28.4         4E‐28    
                      Metal binding          117                    28.1         6E‐13    
                      DNA binding            106                    25.5         1E‐26    
  Ethinicity          1                      Alternative splicing   33           60.0     0.024
                      Splice variant         28                     50.9         0.01     
                      Ubl conjugation        10                     18.2         0.016    
  17                  Splice variant         12                     54.5         0.0028   
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Supplementary Table [S1](#mgg3750-sup-0001){ref-type="supplementary-material"} shows the variants already described associated with the CNVs found in this study. The information of cancer‐related phenotypes, genes, and clinical status were assessed in order to better describe variants and their clinical interpretation. It is worth noting that all variants have been previously linked to breast or other forms of human neoplasms and roughly 60% of the CNVs found are of uncertain significance or have conflict of interpretation. Our observations add up to this data to be part of a more accurate interpretation in the future.

4. DISCUSSION {#mgg3750-sec-0008}
=============

The results shown describe altered chromosome regions that better classify tumors according to their histological type, ethnicity, disease stage, and familial history. For this set of tumors, almost half of CNVs were present in chromosomes 1 and 8 in mucinous tumors. Similarly, approximately half of the CNVs were found in chromosome 19 when considering cases with later disease stage, and in chromosome 21 when considering cases with presence of family history. Virtually 1/3 of the CNVs were found on chromosomes 1 and 17 when considering cases classified by ethnicity. Also, genes found in CNV regions described in this study were significantly enriched in gene sets related to alternative splicing, polymorphisms, DNA‐binding, transcriptional regulation, phosphoproteins, and mutagenic sites, among others.

Polymorphisms of single nucleotides or of larger DNA fragments and all the other above mentioned pathways are widely associated with the development of cancer in general. Aberrant activation of these pathways in breast cancer is part of the oncogenic mechanisms contributing to disease progression and is the focus of many current studies, since the disruption of mechanisms affected by these pathways may lead to pathogenic events (Mocellin, Valpione, Rossri, & Pooley, [2018](#mgg3750-bib-0021){ref-type="ref"}; Nicolini, [2017](#mgg3750-bib-0022){ref-type="ref"}.; Ziv et al., [2017](#mgg3750-bib-0041){ref-type="ref"}). The description of these changes is very relevant from the point of view of genetic susceptibility.

Alternative splicing has been extensively linked to activation of many tumor processes, because RNA processing is vital for the production of variant proteins that are involved in steps such as angiogenesis, invasion, and antiapoptosis. These processes are also influenced not only by genetic but also environmental factors, for example, chemical and immune responses, heat stress, and DNA damage (Anczuków & Krainer, [2016](#mgg3750-bib-0002){ref-type="ref"}; Pai & Luca, [2018](#mgg3750-bib-0027){ref-type="ref"}). Copy number alterations were described as having a particular association to alternative splicing, especially large ones, as seen in our study (Sebestyén et al., [2016](#mgg3750-bib-0032){ref-type="ref"}; Singh & Eyras, [2017](#mgg3750-bib-0034){ref-type="ref"}). Also, hereditary breast cancer was reported as enriched for splicing mutations, what often leads to loss of functions in cancer (Rhine et al., [2018](#mgg3750-bib-0030){ref-type="ref"}).

Thus, in relation to clinical features, namely histological type, ethnicity, disease stage, and familial history, there are particularities worth pointing out. As previously stated, CNVs in chromosomes 1, 8, 17, 19, and 21 explain around half of the alterations found in these samples when associated with one of these clinical characteristics. Alterations in chromosome 1 have been described in 50%--60% of breast tumors and are associated with disease initiation, presence of amplification sites, and a large number of copy number alterations, especially in the 1q arm, which harbor many oncogenes as *MYCL1*, *JUN*, *NRAS*, *SHC1,* and *NCSTN*, for example, all verified in samples from our current study (Goh et al., [2017](#mgg3750-bib-0011){ref-type="ref"}; Orsetti et al., [2006](#mgg3750-bib-0026){ref-type="ref"}; Silva et al., [2015](#mgg3750-bib-0033){ref-type="ref"}). Chromosome 8p arm CNVs are widely linked to poor prognosis and metabolic disruptions in breast cancer; moreover, recent studies showed that loss of multiple genes in this region may create greater genomic instability, leading to different effects from loss of a single gene (Cai et al., [2016](#mgg3750-bib-0005){ref-type="ref"}; Lebok et al., [2015](#mgg3750-bib-0017){ref-type="ref"}). These two chromosomes are mainly associated with differentiation of ductal and mucinous types, which explain why they were found linked to histological type alterations (Afghahi et al., [2015](#mgg3750-bib-0001){ref-type="ref"}; Lacroix‐Triki et al., [2010](#mgg3750-bib-0016){ref-type="ref"}).

Ethnicity was found to be associated with CNVs on chromosomes 1 and 17. A recent study suggests that genes near *BRCA1* in 17q are correlated with breast cancer in African Americans (Ochs‐Balcom et al., [2015](#mgg3750-bib-0024){ref-type="ref"}). However, there is a lack of studies that confirm this association, although genes related to heredity could also contribute to this finding. Interestingly, familial history presence correlated mainly to CNVs in chromosome 21. The gene *NRIP1* localized at 21q21 was described to be a susceptibility locus (Ghoussaini et al., [2012](#mgg3750-bib-0009){ref-type="ref"}) and this region was among our identified CNVs. Also, other chromosome 21 regions were identified, containing genes as *SAMSN1*, associated with several cancer types such as multiple myeloma, lung cancer, glioblastoma, and *RUNX1*, implicated as an oncogene and tumor suppressor in breast cancer (Browne et al., [2015](#mgg3750-bib-0004){ref-type="ref"}; Mercado‐Matos, Matthew‐Onabanjo, & Shaw, [2017](#mgg3750-bib-0020){ref-type="ref"}; Noll et al., [2014](#mgg3750-bib-0023){ref-type="ref"}; Yamada et al., [2008](#mgg3750-bib-0038){ref-type="ref"}; Yan et al., [2013](#mgg3750-bib-0039){ref-type="ref"}). Late disease stage was correlated to chromosome 19 copy number alterations. These regions have been described in association with high‐grade breast cancers for other studies (Yu, Kanaan, Bae, Baed, & Gabrielson, [2009](#mgg3750-bib-0040){ref-type="ref"}) and are characterized by aggressiveness and poor prognosis tumors.

Since this study focused on a Brazilian cohort, it is worth mentioning that the genetic composition of the Brazilian population is sharply mixed and is genomically underrepresented in studies that consider variants and tumor markers (Popejoy & Fullerton, [2016](#mgg3750-bib-0029){ref-type="ref"}). There might be considerable genetic differences underlying tumor biology in these cases, so it is critical to consider understudied populations to better understand breast cancer worldwide. Despite the restricted sample size, this is the first study to evaluate breast cancer CNVs in this specific population, associating them to tumor clinical features. CNV regions identified from these samples and their correlated genes could potentially be different from non‐Brazilian cohorts. In a previous study comparing Brazilian and TCGA (The Cancer Genome Atlas) data (data not shown), we found striking differences between these two cohorts, which were related to genes involved in different carcinogenic pathways, since pathways related to FGF and Wnt were most commonly affected in the Brazilian samples, whereas those associated with cholecystokinin receptor (CCKR) signaling and inflammation mediated by chemokine and cytokine signaling pathways were most commonly affected in the TCGA samples.

We conclude that the copy number alterations described in this study provide an overview of the chromosomal regions affected by CNVs and their association with clinical and pathological features. New molecular targets can be inferred from this study and these CNV regions should be investigated in more detail, potentially driving more dedicated studies focusing on breast tumors from Brazilian cohorts.
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